You are here

  • Home
  • Archive
  • Volume 71, Issue 3
  • Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise Report
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration

Authors

  1. Correspondence to Professor Cem Gabay, Department of Rheumatology, University Hospitals of Geneva, 26 Avenue Beau-Séjour, 1211 Geneva 14, Switzerland; cem.gabay{at}hcuge.ch for the SCQM Registry
View Full Text

Citation

Chatzidionysiou K, Lie E, Nasonov E, et al
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Annals of the Rheumatic Diseases 2012;71:374-377.

Publication history

  • Received April 8, 2011
  • Accepted September 4, 2011
  • First published October 4, 2011.
Online issue publication 
February 06, 2012

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions